WallStSmart

POMDOCTOR LIMITED American Depositary Shares (POM)vsScienture Holdings, Inc. (SCNX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

POMDOCTOR LIMITED American Depositary Shares generates 56048% more annual revenue ($366.86M vs $653,390). SCNX leads profitability with a 0.0% profit margin vs -40.6%. SCNX earns a higher WallStSmart Score of 33/100 (F).

POM

Avoid

28

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 5.0
Piotroski: 4/9Altman Z: -66.56

SCNX

Avoid

33

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 8.3Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for POM.

SCNXUndervalued (+91.2%)

Margin of Safety

+91.2%

Fair Value

$5.10

Current Price

$0.46

$4.64 discount

UndervaluedFair: $5.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

POM2 strengths · Avg: 9.0/10
Debt/EquityHealth
-0.1910/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
16.2%8/10

16.2% revenue growth

SCNX2 strengths · Avg: 10.0/10
P/E RatioValuation
0.7x10/10

Attractively priced relative to earnings

Price/BookValuation
0.1x10/10

Reasonable price relative to book value

Areas to Watch

POM4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$40.13M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-16.17M2/10

Negative free cash flow — burning cash

SCNX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$19.69M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-24.1%2/10

ROE of -24.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : POM

The strongest argument for POM centers on Debt/Equity, Revenue Growth. Revenue growth of 16.2% demonstrates continued momentum.

Bull Case : SCNX

The strongest argument for SCNX centers on P/E Ratio, Price/Book.

Bear Case : POM

The primary concerns for POM are EPS Growth, Market Cap, Return on Equity.

Bear Case : SCNX

The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

POM profiles as a growth stock while SCNX is a value play — different risk/reward profiles.

POM is growing revenue faster at 16.2% — sustainability is the question.

SCNX generates stronger free cash flow (-3M), providing more financial flexibility.

Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SCNX scores higher overall (33/100 vs 28/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

POMDOCTOR LIMITED American Depositary Shares

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Pomdoctor Limited, offers an online B2C portal to sell pharmaceutical products. The company is headquartered in Guangzhou, China.

Visit Website →

Scienture Holdings, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Scienture Holdings, Inc. (SCNX) is an innovative biotechnology company focused on developing cutting-edge therapeutic solutions for neurological disorders. With a robust drug development pipeline supported by advanced technology and a highly skilled research team, Scienture is committed to meeting unmet medical needs and improving patient outcomes. The company's strategic emphasis on scientific excellence, regulatory compliance, and collaborative partnerships positions it well for growth within the burgeoning healthcare sector, highlighting its potential to make significant contributions to global health advancements.

Want to dig deeper into these stocks?